Published in Gastroenterology on March 24, 2011
Hepatocellular carcinoma: clinical frontiers and perspectives. Gut (2014) 5.79
Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer (2013) 2.87
Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology (2013) 2.21
Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis. Gastroenterology (2013) 2.13
Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. Oncotarget (2012) 1.55
Hepatocellular Carcinoma From Epidemiology to Prevention: Translating Knowledge into Practice. Clin Gastroenterol Hepatol (2015) 1.45
Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges. Curr Cancer Drug Targets (2012) 1.23
Epidermal growth factor gene polymorphism and risk of hepatocellular carcinoma: a meta-analysis. PLoS One (2012) 1.10
Virus associated malignancies: the role of viral hepatitis in hepatocellular carcinoma. Semin Cancer Biol (2014) 1.04
ABO blood group and the risk of hepatocellular carcinoma: a case-control study in patients with chronic hepatitis B. PLoS One (2012) 0.98
Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma. J Hepatol (2014) 0.96
Hepatitis C virus and hepatocarcinogenesis. Clin Mol Hepatol (2012) 0.96
Hepatitis C virus-induced hepatocellular carcinoma. Clin Mol Hepatol (2015) 0.91
EGFR Signaling in Liver Diseases. Int J Mol Sci (2015) 0.90
Association of epidermal growth factor and epidermal growth factor receptor polymorphisms with the risk of hepatitis B virus-related hepatocellular carcinoma in the population of North China. Genet Test Mol Biomarkers (2013) 0.89
Genetics Variants and Serum Levels of MHC Class I Chain-related A in Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis C Patients Post Antiviral Treatment. EBioMedicine (2016) 0.88
Ultrasound elastography for fibrosis surveillance is cost effective in patients with chronic hepatitis C virus in the UK. Dig Dis Sci (2013) 0.88
β-PDGF receptor expressed by hepatic stellate cells regulates fibrosis in murine liver injury, but not carcinogenesis. J Hepatol (2015) 0.86
Genetic signatures in choline and 1-carbon metabolism are associated with the severity of hepatic steatosis. FASEB J (2013) 0.85
Epidermal growth factor 61A>G polymorphism is associated with risk of hepatocellular carcinoma: a meta-analysis. Genet Test Mol Biomarkers (2012) 0.84
Development and validation of a clinical scoring system for predicting risk of HCC in asymptomatic individuals seropositive for anti-HCV antibodies. PLoS One (2014) 0.83
Hepatocellular carcinoma in chronic hepatitis C: from bench to bedside. Semin Immunopathol (2012) 0.83
Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: Epidemiology, Pathogenesis, and Prevention. J Clin Transl Hepatol (2013) 0.81
Host genetics predict clinical deterioration in HCV-related cirrhosis. PLoS One (2014) 0.81
Genetic polymorphisms of epidermal growth factor in relation to risk of hepatocellular carcinoma: two case-control studies. BMC Gastroenterol (2013) 0.80
A functional polymorphism in the epidermal growth factor gene predicts hepatocellular carcinoma risk in Japanese hepatitis C patients. Onco Targets Ther (2013) 0.80
Hepatocarcinogenesis associated with hepatitis B, delta and C viruses. Curr Opin Virol (2016) 0.79
Individualized hepatocellular carcinoma risk: the challenges for designing successful chemoprevention strategies. World J Gastroenterol (2013) 0.79
Association between epidermal growth factor gene +61A/G polymorphism and the risk of hepatocellular carcinoma: a meta-analysis based on 16 studies. BMC Cancer (2015) 0.78
Genetic testing for hepatocellular carcinoma: an ambitious goal still to achieve. J Hepatol (2012) 0.78
Molecular prognostic prediction in liver cirrhosis. World J Gastroenterol (2015) 0.77
Aberrant Cosmc genes result in Tn antigen expression in human colorectal carcinoma cell line HT-29. Int J Clin Exp Pathol (2015) 0.77
Epidermal growth factor receptor pathway polymorphisms and the prognosis of hepatocellular carcinoma. Am J Cancer Res (2014) 0.77
Impact of epidermal growth factor single-nucleotide polymorphism on recurrence of hepatocellular carcinoma after hepatectomy in patients with chronic hepatitis C virus infection. Cancer Sci (2014) 0.77
Significant change of cytochrome P450s activities in patients with hepatocellular carcinoma. Oncotarget (2016) 0.76
Kenneth tanabe works to solve the mysteries of liver cancer: while progress has been relatively slow, this noted expert sees reasons for hope. P T (2015) 0.75
Cost-Effectiveness of Risk Score-Stratified Hepatocellular Carcinoma Screening in Patients with Cirrhosis. Clin Transl Gastroenterol (2017) 0.75
Tailored algorithms for hepatocellular carcinoma surveillance: Is one-size-fits-all strategy outdated? Curr Hepatol Rep (2017) 0.75
Impact of EGF, IL28B, and PNPLA3 polymorphisms on the outcome of allograft hepatitis C: a multicenter study. Clin Transplant (2016) 0.75
Quantitative assessment of the effect of epidermal growth factor 61A/G polymorphism on the risk of hepatocellular carcinoma. Oncol Lett (2015) 0.75
Processes to manage analyses and publications in a phase III multicenter randomized clinical trial. Trials (2014) 0.75
Personalized management of hepatocellular carcinoma based on molecular information: future prospects. Clin Liver Dis (Hoboken) (2015) 0.75
Molecular Epidemiology of Hepatocellular Carcinoma. Clin Liver Dis (Hoboken) (2012) 0.75
Prediction models of hepatocellular carcinoma development in chronic hepatitis B patients. World J Gastroenterol (2016) 0.75
Global cancer statistics, 2002. CA Cancer J Clin (2005) 119.22
Management of hepatocellular carcinoma. Hepatology (2005) 27.42
Histological grading and staging of chronic hepatitis. J Hepatol (1995) 19.57
The global health burden of infection-associated cancers in the year 2002. Int J Cancer (2006) 13.57
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med (2008) 9.33
Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med (2008) 9.20
Molecular targeted therapies in hepatocellular carcinoma. Hepatology (2008) 6.16
Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology (2008) 6.15
Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med (1993) 5.32
Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology (2008) 4.73
Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology (2003) 4.72
Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol (2001) 4.46
Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut (2001) 4.12
Association between functional polymorphism in EGF gene and malignant melanoma. Lancet (2002) 2.48
Human plasma epidermal growth factor/beta-urogastrone is associated with blood platelets. J Clin Invest (1983) 2.24
A scan of chromosome 10 identifies a novel locus showing strong association with late-onset Alzheimer disease. Am J Hum Genet (2005) 2.04
The EGF receptor is required for efficient liver regeneration. Proc Natl Acad Sci U S A (2007) 2.00
Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. JAMA (2008) 1.94
Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis. Hepatology (2005) 1.90
A functional epidermal growth factor (EGF) polymorphism, EGF serum levels, and esophageal adenocarcinoma risk and outcome. Clin Cancer Res (2008) 1.27
Biological effect of epidermal growth factor on the in vitro growth of human tumors. Cancer Res (1987) 1.25
Expression of epidermal growth factor and its receptor in cirrhotic liver disease. J Histochem Cytochem (2000) 1.15
Detection of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver: accuracy of ultrasonography in transplant patients. J Ultrasound Med (2001) 1.13
Prognostic value of Ishak fibrosis stage: findings from the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology (2010) 1.12
Serum alpha-fetoprotein levels and liver histology in patients with chronic hepatitis C. Am J Gastroenterol (1998) 1.11
Autocrine mitogen IgEGF cooperates with c-myc or with the Hcs locus during hepatocarcinogenesis in transgenic mice. Oncogene (1995) 1.08
Epidermal growth factor secreted from the salivary gland is necessary for liver regeneration. Am J Physiol (1995) 1.05
Homogeneous allele-specific PCR in SNP genotyping. Methods Mol Biol (2003) 1.04
Influence of epidermal growth factor on liver regeneration after partial hepatectomy in mice. J Endocrinol (1991) 1.02
Association between epidermal growth factor 61A/G polymorphism and hepatocellular carcinoma susceptibility in Chinese patients. Liver Int (2009) 0.97
Association between EGF promoter polymorphisms and cancer risk: a meta-analysis. Med Oncol (2009) 0.96
Growth factors as therapeutic targets in HCC. Crit Rev Oncol Hematol (2008) 0.95
Sequential assessment of the intrahepatic expression of epidermal growth factor and transforming growth factor-beta1 in hepatofibrogenesis of a rat cirrhosis model. Int J Mol Med (2007) 0.91
The dual EGF/VEGF receptor tyrosine kinase inhibitor AEE788 inhibits growth of human hepatocellular carcinoma xenografts in nude mice. Int J Oncol (2008) 0.87
Mitotic responsiveness of cultured adult human hepatocytes to epidermal growth factor, transforming growth factor alpha, and human serum. Gastroenterology (1992) 0.87
Nodules of less-differentiated tumor within or adjacent to hepatocellular carcinoma: relative expression of transforming growth factor-alpha and its receptor in the different areas of tumor. Hum Pathol (1995) 0.86
Regulation of transcription by the rat EGF gene promoter in normal and ischemic murine kidney cells. Am J Physiol (1995) 0.83
EGFR and VEGFR as potential target for biological therapies in HCC cells. Cancer Lett (2008) 0.80
The A61G EGF polymorphism is associated with development of extraaxial nervous system tumors but not with overall survival. Cancer Genet Cytogenet (2010) 0.79
Epidermal growth factor is decreased in liver of rats with biliary cirrhosis but does not act as paracrine growth factor immediately after hepatectomy. J Hepatol (2000) 0.78
A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am J Hum Genet (2004) 13.71
A high-density admixture map for disease gene discovery in african americans. Am J Hum Genet (2004) 10.87
Natural selection on protein-coding genes in the human genome. Nature (2005) 10.84
Strategies for multivessel revascularization in patients with diabetes. N Engl J Med (2012) 10.79
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med (2008) 9.33
Inferring nonneutral evolution from human-chimp-mouse orthologous gene trios. Science (2003) 9.20
Assessing the evolutionary impact of amino acid mutations in the human genome. PLoS Genet (2008) 8.92
Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet (2006) 8.32
Proportionally more deleterious genetic variation in European than in African populations. Nature (2008) 6.61
A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet (2013) 6.19
Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology (2008) 6.15
Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis (2002) 5.34
Assessment of cumulative evidence on genetic associations: interim guidelines. Int J Epidemiol (2007) 4.96
Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology (2009) 4.90
A TALEN genome-editing system for generating human stem cell-based disease models. Cell Stem Cell (2012) 4.49
Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology (2003) 4.33
Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology (2004) 4.27
A functional genomic screen identifies cellular cofactors of hepatitis C virus replication. Cell Host Microbe (2009) 4.24
Hepatic portal venous gas: the ABCs of management. Arch Surg (2009) 3.76
Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology (2009) 3.50
Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials (2004) 3.46
Ex vivo analysis of human memory CD4 T cells specific for hepatitis C virus using MHC class II tetramers. J Clin Invest (2003) 3.40
Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology (2010) 3.35
Perspective: a culture of respect, part 1: the nature and causes of disrespectful behavior by physicians. Acad Med (2012) 3.28
A road map for efficient and reliable human genome epidemiology. Nat Genet (2006) 3.21
Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst (2006) 3.17
Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. Hepatology (2008) 3.14
Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist (2011) 3.05
Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol (2010) 2.96
High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. Gastroenterology (2004) 2.91
CD8 epitope escape and reversion in acute HCV infection. J Exp Med (2004) 2.77
Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells. Cancer Res (2008) 2.71
Case records of the Massachusetts General Hospital. Case 23-2005. A 57-year-old man with a mass in the liver. N Engl J Med (2005) 2.67
Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol (2005) 2.63
Reporting, appraising, and integrating data on genotype prevalence and gene-disease associations. Am J Epidemiol (2002) 2.56
Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology (2010) 2.47
Apolipoprotein B-dependent hepatitis C virus secretion is inhibited by the grapefruit flavonoid naringenin. Hepatology (2008) 2.45
Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology (2008) 2.44
Epithelial-to-mesenchymal transition predicts prognosis of pancreatic cancer. Surgery (2013) 2.43
Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma. Hepatology (2014) 2.40
The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C. Liver Int (2009) 2.33
Development of an accurate index for predicting outcomes of patients with acute liver failure. Gastroenterology (2012) 2.26
A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. Hepatology (2007) 2.16
Genome-wide association studies, field synopses, and the development of the knowledge base on genetic variation and human diseases. Am J Epidemiol (2009) 2.15
American Gastroenterological Association medical position statement on the management of hepatitis C. Gastroenterology (2006) 2.14
Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up. Hepatology (2009) 2.13
Viral sequence evolution in acute hepatitis C virus infection. J Virol (2007) 2.13
Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis. Gastroenterology (2013) 2.13
Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology (2006) 2.06
Perspective: a culture of respect, part 2: creating a culture of respect. Acad Med (2012) 2.06
Comprehensive analysis of CD8(+)-T-cell responses against hepatitis C virus reveals multiple unpredicted specificities. J Virol (2002) 2.03
Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology (2008) 2.02
Hemojuvelin regulates hepcidin expression via a selective subset of BMP ligands and receptors independently of neogenin. Blood (2008) 2.01
High level of PD-1 expression on hepatitis C virus (HCV)-specific CD8+ and CD4+ T cells during acute HCV infection, irrespective of clinical outcome. J Virol (2007) 2.01
Broad specificity of virus-specific CD4+ T-helper-cell responses in resolved hepatitis C virus infection. J Virol (2002) 1.98
Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C. Hepatology (2011) 1.98
Evolutionary processes acting on candidate cis-regulatory regions in humans inferred from patterns of polymorphism and divergence. PLoS Genet (2009) 1.97
Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. JAMA (2008) 1.94
Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology (2005) 1.93
Identification of four gene variants associated with myocardial infarction. Am J Hum Genet (2005) 1.89
Hepatitis C virus core protein blocks interferon signaling by interaction with the STAT1 SH2 domain. J Virol (2006) 1.87
Hepatitis C virus expression suppresses interferon signaling by degrading STAT1. Gastroenterology (2005) 1.87
Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts. Ann Intern Med (2013) 1.82
Effects of CCR5-Delta32 and CCR2-64I alleles on HIV-1 disease progression: the protection varies with duration of infection. AIDS (2003) 1.81
Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Gastroenterology (2009) 1.80
Coinfection with HIV-1 and HCV--a one-two punch. Gastroenterology (2009) 1.78
Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut (2010) 1.78
Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology (2006) 1.76
Liver transplantation for erythropoietic protoporphyria liver disease. Liver Transpl (2005) 1.76
Non-high-density lipoprotein cholesterol as a biomarker for nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol (2012) 1.74
Influence of high body mass index on outcome in acute liver failure. Clin Gastroenterol Hepatol (2006) 1.74
Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C. Gastroenterology (2006) 1.73
Psychiatric comorbidity in adult attention deficit hyperactivity disorder: findings from multiplex families. Am J Psychiatry (2005) 1.73
Functional linkage of cirrhosis-predictive single nucleotide polymorphisms of Toll-like receptor 4 to hepatic stellate cell responses. Hepatology (2009) 1.72
DNA polymorphisms and response to treatment in patients with chronic hepatitis C: results from the HALT-C trial. J Hepatol (2008) 1.71
Biology of desmoplastic melanoma: a case-control comparison with other melanomas. J Clin Oncol (2005) 1.71
Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial. Clin Gastroenterol Hepatol (2007) 1.71
Testing strategy to identify cases of acute hepatitis C virus (HCV) infection and to project HCV incidence rates. J Clin Microbiol (2007) 1.70
Middle pancreatectomy: safety and long-term results. Surgery (2009) 1.69
Spontaneous resolution of chronic hepatitis C virus disease after withdrawal of immunosuppression. Gastroenterology (2003) 1.68